Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow Health | 19.04% | Add +1.8% | 3,990,000 | $20.89 | $83M | +69,400 | +$31M |
| TGTX - Tg Therapeutics | 9.27% | Hold | 2,280,000 | $17.79 | $41M | — | — |
| OCUL - Ocular Therapeutix | 8.29% | Reduce −20.2% | 5,307,500 | $6.84 | $36M | −1,345,638 | −$24M |
| RYTM - Rhythm Pharmaceuticals | 4.83% | Hold | 515,000 | $41.06 | $21M | — | — |
| Keros Therapeutics | 3.84% | Hold | 367,500 | $45.70 | $17M | — | — |
| ARVN - Arvinas | 3.38% | Add +68.2% | 555,000 | $26.62 | $15M | +225,000 | +$1M |
| Immunome | 3.05% | New | 1,102,500 | $12.10 | $13M | +1,102,500 | +$13M |
| CYTK - Cytokinetics | 2.46% | New | 198,500 | $54.18 | $11M | +198,500 | +$11M |
| CDXS - Codexis | 2.45% | Add +10.7% | 3,455,000 | $3.10 | $11M | +335,000 | −$178K |
| EWTX - Edgewise Therapeutics | 2.39% | Reduce −12.8% | 580,000 | $18.01 | $10M | −85,000 | −$2M |
| Catalyst Pharmaceuticals | 2.27% | Reduce −36.3% | 640,000 | $15.49 | $10M | −364,355 | −$6M |
| Cargo Therapeutics | 2.08% | New | 555,700 | $16.42 | $9M | +555,700 | +$9M |
| Jasper Therapeutics | 2.03% | Reduce −10.0% | 392,000 | $22.70 | $9M | −43,573 | −$4M |
| NRIX - Nurix Therapeutics | 2.00% | New | 418,928 | $20.87 | $9M | +418,928 | +$9M |
| TRVI - Trevi Therapeutics | 1.80% | Hold | 2,645,000 | $2.98 | $8M | — | — |
| ETON - Eton Pharmaceuticals | 1.80% | Reduce −2.1% | 2,395,000 | $3.29 | $8M | −50,781 | −$1M |
| APLT - Applied Therapeutics ' | 1.79% | Reduce −5.1% | 1,680,000 | $4.67 | $8M | −90,000 | +$4M |
| FDMT - 4D Molecular Therapeutics | 1.66% | Add +0.5% | 345,750 | $20.99 | $7M | +1,627 | −$4M |
| IOVA - Iovance Biotherapeutics | 1.64% | Hold | 897,000 | $8.02 | $7M | — | — |
| Acelyrin | 1.59% | Hold | 1,580,000 | $4.41 | $7M | — | — |
| URGN - Urogen Pharma | 1.58% | Add +52.6% | 412,000 | $16.78 | $7M | +142,000 | +$3M |
| PCVX - Vaxcyte | 1.47% | Hold | 85,000 | $75.51 | $6M | — | — |
| Biodesix | 1.41% | Add +651.9% | 4,020,000 | $1.53 | $6M | +3,485,343 | +$5M |
| NAMS - Newamsterdam Pharma | 1.38% | Reduce −0.1% | 315,000 | $19.21 | $6M | −388 | −$1M |
| XOMA - XOMA Del | 1.35% | Hold | 250,000 | $23.69 | $6M | — | — |
| Protara Therapeutics | 1.21% | Reduce −14.4% | 2,304,262 | $2.30 | $5M | −388,332 | −$5M |
| INTC - Intellia Therapeutics | 1.11% | Reduce −14.5% | 218,000 | $22.38 | $5M | −37,000 | −$2M |
| NUVL - Nuvalent | 1.03% | New | 59,300 | $75.86 | $4M | +59,300 | +$4M |
| Syros Pharmaceuticals | 1.02% | Add +9.9% | 865,443 | $5.16 | $4M | +77,898 | +$253K |
| LQDA - Liquidia | 0.89% | Reduce −17.7% | 325,000 | $12.00 | $4M | −70,000 | −$2M |
| PTGX - Protagonist Therapeutics | 0.83% | Reduce −6.8% | 105,000 | $34.65 | $4M | −7,700 | +$378K |
| Gossamer Bio | 0.80% | Add +60.2% | 3,910,000 | $0.9009 | $4M | +1,469,891 | +$643K |
| Lexicon Pharmaceuticals | 0.72% | New | 1,875,000 | $1.68 | $3M | +1,875,000 | +$3M |
| Savara | 0.66% | Reduce −16.4% | 714,960 | $4.03 | $3M | −140,040 | −$1M |
| Allakos | 0.64% | Add +14.2% | 2,780,000 | $1.00 | $3M | +345,000 | −$288K |
| Ventyx Biosciences | 0.63% | Reduce −7.4% | 1,190,000 | $2.31 | $3M | −95,000 | −$4M |
| VSTM - Verastem | 0.62% | Add +332.8% | 915,000 | $2.98 | $3M | +703,600 | +$232K |
| Regulus Therapeutics | 0.60% | Add +766.1% | 1,475,000 | $1.78 | $3M | +1,304,692 | +$2M |
| Lyell Immunopharma | 0.55% | Reduce −50.2% | 1,670,000 | $1.45 | $2M | −1,685,000 | −$5M |
| RLMD - Relmada Therapeutics | 0.41% | Reduce −20.9% | 600,000 | $3.00 | $2M | −159,000 | −$2M |
| FULC - Fulcrum Therapeutics | 0.40% | Add +119.2% | 285,000 | $6.20 | $2M | +155,000 | +$540K |
| Karyopharm Therapeutics | 0.28% | New | 1,425,000 | $0.8676 | $1M | +1,425,000 | +$1M |
| IBIO — | 0.18% | Reduce −44.9% | 375,000 | $2.11 | $791K | −305,000 | −$2M |
| Pmv Pharmaceuticals | 0.18% | Add +0.7% | 475,000 | $1.62 | $770K | +3,519 | −$33K |
| Aerovate Therapeutics | 0.17% | New | 440,000 | $1.66 | $730K | +440,000 | +$730K |
| DSGN - Design Therapeutics | 0.16% | Add +81.4% | 205,000 | $3.35 | $687K | +91,962 | +$231K |
| ABCL - Abcellera Biologics | 0.14% | New | 200,000 | $2.96 | $592K | +200,000 | +$592K |
| Aligos Therapeutics | 0.10% | Reduce −22.7% | 1,260,000 | $0.3500 | $441K | −370,000 | −$1M |
| Reneo Pharmaceuticals | 0.06% | New | 165,000 | $1.51 | $249K | +165,000 | +$249K |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2024 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| CMPX - Compass Therapeutics | 1.44% | Exit | 0 | $1.98 | $6M | −3,170,000 | −$6M |
| Nyxoah S A | 0.99% | Exit | 0 | $13.49 | $4M | −320,000 | −$4M |
| Revance Therapeutics | 0.88% | Exit | 0 | $4.92 | $4M | −785,000 | −$4M |
| ZNTL - Zentalis Pharmaceuticals | 0.72% | Exit | 0 | $15.76 | $3M | −200,000 | −$3M |
| CNTX - Context Therapeutics | 0.35% | Exit | 0 | $1.38 | $2M | −1,108,357 | −$2M |
| PGEN - Precigen | 0.31% | Exit | 0 | $1.45 | $1M | −947,500 | −$1M |
| LRMR - Larimar Therapeutics | 0.30% | Exit | 0 | $7.59 | $1M | −174,413 | −$1M |
| Morphosys AG | 0.27% | Exit | 0 | $18.14 | $1M | −65,000 | −$1M |
| GKOS - Glaukos | 0.19% | Exit | 0 | $94.33 | $809K | −8,576 | −$809K |
| REPARE THERAPEUTICS | 0.07% | Exit | 0 | $4.71 | $318K | −67,561 | −$318K |
| CRNX - Crinetics Pharmaceuticals | 0.05% | Exit | 0 | $1.00 | $210K | −210,000 | −$210K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2